The Acute Liver Failure Study Group (ALFSG) is a clinical research network funded by the National Institutes of Health since 1997, to gather important prospective data and biosamples on this rare condition. 

In the Zhang Lab, we seek to understand the molecular mechanisms of metabolic diseases, with the long-term goal of creating novel therapeutic strategies.

The goal of our research is to identify key immune checkpoints of gastrointestinal disorders that could be targeted for therapeutic intervention and drug development.

Burstein Laboratory focuses on understanding the regulation of the inflammatory response at a molecular level, and elucidating how these events may participate in human disease.